(Q54637612)

1 June 2018

title

mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. (English)

1 reference

1 June 2018

author

Helena Pópulo

1

1 reference

1 June 2018

Paula Soares

2

1 reference

1 June 2018

José Manuel Lopes

7

1 reference

1 June 2018

author name string

A Faustino

3

1 reference

1 June 2018

A S Rocha

4

1 reference

1 June 2018

P Silva

5

1 reference

1 June 2018

F Azevedo

6

1 reference

1 June 2018

publication date

19 November 2010

1 reference

1 June 2018

Pigment Cell & Melanoma Research

published in

1 reference

1 June 2018

volume

24

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

254-257

1 reference

1 June 2018

A negative feedback signaling network underlies oncogene-induced senescence

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Toward a molecular classification of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

mTOR is activated in the majority of malignant melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

High BRAF mutation frequency does not characterize all melanocytic tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00796.X

10.1111/J.1755-148X.2010.00796.X

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

release_37b7ceuqrvfyxlvzzncc33uqrm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/37b7ceuqrvfyxlvzzncc33uqrm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21029395

1 reference

1 June 2018